Q1 FY27 results analysis · August 14, 2026

Alkem Laboratories Q1 FY27 Results Analysis: PAT Plunges 21.7%, Margin Compresses 140 bps

−21.7%PAT year on year, Rs. 520.00 Cr
Cofacto ResearchPublished August 14, 20262 min readNegative read
Quick summary

Alkem Laboratories Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 3,740.20 Cr (+10.90% YoY) and PAT growth of -21.70% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 14, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 3,740.20 Cr (+10.90% YoY)
PAT (Q1)Rs. 520.00 Cr (-21.70% YoY)
EBITDA margin20.50% (-140 bps YoY)
EPS (Q1)Rs. 43.49 (-21.70% YoY)
Market capRs. 64,546.71 Cr
CMPRs. 5,368.00

Quarter Snapshot

Revenue grew 10.9% YoY but EBITDA margin compressed 140 bps and PAT declined 21.7% due to tax rate normalization and cost pressures. Management missed guidance on US revenue, margin improvement, and tax rate, while domestic outperformance and non-US international growth were bright spots. Post-quarter events include Daman OAI classification and Occlutech acquisition, adding uncertainty.

Key Investment Insights

Key Positives

  • Domestic revenue grew 10.3% YoY outperforming IPM by 100 bps.
  • Non-US international revenue grew 34.5% YoY, contributing 12.9% of sales.
  • EBITDA margin of 20.5% was within the guided 20-21% band.
  • Net cash improved to Rs.5,764 Cr from Rs.5,474 Cr QoQ.
  • Gross margin expanded 2.6 ppt YoY to 67.9%.

Risk Factors

  • US revenue growth of 6.5% INR implies USD decline, missing high single-digit USD guidance.
  • EBITDA margin compressed 140 bps YoY due to employee cost growth of 16.7% and other expenses growth of 25.6%.
  • Effective tax rate surged to 32.4% from 13.3% YoY, causing PAT decline of 21.7%.
  • Daman facility received OAI classification post-quarter, overhang on US business.
  • CEO resignation effective 30-Jun-2026 with no successor announced.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.